This website uses cookies to enhance the user experience.
SERO AS

SERO AS912 228 738

Process industry
Limited company
Stasjonsveien 44 1396 BILLINGSTAD, Norge

SERO AS

SERO is a Norwegian company providing high quality materials for control and calibration of laboratory and primary health care analytical instruments.

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Links

Organization

Chairman of the board
Years since formation
29 years
since Mar 12, 1995
Type
Limited company
VAT registered
Yes
Number of employees
69

Ownership

Number of shares and share classes
100,000
1 share class
Total number of shareholders
5
persons

Financials

Total operating income 2023
167,321,410
NOK
Annual total result 2023
30,504,588
NOK
Total equity 2023
134,206,196
NOK
Last update: Oct 14, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman
50.5 %
directly
Deputy Chair
9 %
directly
Board Member-
Board Member
9 %
directly
Board Member-
Alternate Member
22.5 %
directly
Board Member-
Board Member
9 %
directly
Alternate Member-
Alternate Member-

Others

NameRoleShares
B
BDO AS
Auditor-

Top 10 individual shareholders

NameRoleShares
Chairman
50.5 %
directly
Alternate Member
22.5 %
directly
Deputy Chair
9 %
directly
Board Member
9 %
directly
Board Member
9 %
directly
Last update: Oct 3, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
Ordinary shares
50,500
50.5 %
Ordinary shares
22,500
22.5 %
Ordinary shares
9,000
9 %
Ordinary shares
9,000
9 %
Ordinary shares
9,000
9 %
Last update: May 24, 2024

Financials

in NOK

Summary

Year202320222021
Total operating income
167,321,410
146,419,289
133,918,790
Annual Total Result
30,504,588
20,440,639
20,469,888
Total assets
179,153,159
154,848,197
144,672,567
Total liabilities
44,946,963
39,146,589
39,411,597
Total equity
134,206,196
115,701,608
105,260,969

P&L

Year202320222021
Total operating income
167,321,410
146,419,289
133,918,790
Total operating costs
127,657,447
121,444,190
108,494,371
Operating result
39,663,963
24,975,099
25,424,420
Financial income/costs
-637,922
1,154,911
724,969
Profit before tax
39,026,042
26,130,010
26,149,389
Total tax & extraordinary income/cost
8,521,454
5,689,371
5,679,501
Annual Total Result
30,504,588
20,440,639
20,469,888

Balance overview

Year202320222021
Total fixed assets
9,545,408
6,406,487
4,507,698
Total current assets
169,607,751
148,441,710
140,164,868
Total assets
179,153,159
154,848,197
144,672,567
Short term debt
40,845,608
32,757,830
32,429,311
Long term debt
4,101,356
6,388,758
6,982,286
Total liabilities
44,946,963
39,146,589
39,411,597
Contributed capital
10,000,000
10,000,000
10,000,000
Retained earnings
124,206,196
105,701,608
95,260,969
Total equity
134,206,196
115,701,608
105,260,969
Total equity and liabilities
179,153,159
154,848,197
144,672,567

Classification

Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations